Axonics Modulation Technologies Inc. (Nasdaq: AXNX) in Irvine priced 5 million shares of common stock at $22 a share. It expects $101 million in proceeds after expenses.
Shares in the company, which makes products to treat bladder and bowel dysfunction, rose last week following FDA approval of a flagship device and positively received quarterly results.
Over the last two sessions, its share price dropped back to about $21.45 apiece and a $615 million market cap.
For more on Axonics see the Nov. 25 print edition of the Business Journal.